阿尔茨海默病生物标志物的时间动态与生物学变异性
这项多中心队列研究于2016至2023年纳入2611例认知正常、轻度认知障碍或阿尔茨海默型痴呆个体,比较血浆生物标志物与PET结果不一致组和一致组的临床特征及认知变化。p-tau217与Aβ PET一致性最高(90.5%),p-tau217+/Aβ PET-组年龄更大且高血压、糖尿病、慢性肾脏病患病率更高,海马体积更低且临床轨迹更差。
要点
- p-tau217与Aβ PET一致性率90.5%(2326/2571),与tau PET一致性率83.3%(100/120)。
- p-tau217+/Aβ PET-组较p-tau217-/Aβ PET-组年龄更大,高血压、糖尿病、慢性肾脏病患病率更高。
- 仅p-tau217+/tau PET+组较p-tau217-/tau PET-组认知下降更快(β=-1.66,P<.001)。
核心结论
- 研究结果提示血浆生物标志物与PET结果不一致的机制可能是多方面的,强调需考虑血浆生物标志物的时间动态和生物学变异性。
研究设计与样本
- 多中心队列研究,2016至2023年纳入2611例认知正常、轻度认知障碍或阿尔茨海默型痴呆且同时具有Aβ PET和血浆生物标志物的个体,其中124例额外接受tau PET。
主要发现
- p-tau217与Aβ PET一致性率为90.5%(2326/2571),与tau PET一致性率为83.3%(100/120)。
- p-tau217+/Aβ PET-组较p-tau217-/Aβ PET-组年龄更大(均值[SD] 75.8[7.2]岁 vs 70.0[8.8]岁,P<.001),高血压(56/152[36.8%] vs 266/1073[25.0%])、糖尿病(40/152[26.3%] vs 156/1059[14.7%])、慢性肾脏病(17/152[11.2%] vs 21/1073[2.0%])患病率更高(P均<.001)。
- p-tau217-/Aβ PET+组体质指数高于p-tau217+/Aβ PET+组(均值[SD] 24.1[2.8] vs 23.1[3.1],P=.001)。
- p-tau217+/Aβ PET-组较p-tau217-/Aβ PET-组海马体积更低(均值[SD] 2555.4[576.9] vs 2979.1[545.8],P<.001)且临床轨迹更差(β=-0.53,P<.001)。
- tau PET不一致组与p-tau217-/tau PET-组相比,医学共病或临床结局无显著差异;仅p-tau217+/tau PET+组较p-tau217-/tau PET-组认知下降更快(β=-1.66,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding the characteristics of discordance between plasma biomarkers and positron emission tomography (PET) results in Alzheimer disease (AD) is crucial for accurate interpretation of the findings. OBJECTIVE: To compare (1) medical comorbidities affecting plasma biomarker concentrations, (2) imaging and clinical features, and (3) cognitive changes between plasma biomarker and PET discordant and concordant cases. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study, conducted between 2016 and 2023, included individuals with unimpaired cognition, mild cognitive impairment, or Alzheimer-type dementia, who had both amyloid β (Aβ) PET imaging and plasma biomarkers. A subset of participants also underwent tau PET imaging. EXPOSURES: Participants were categorized into 4 groups based on their plasma and PET biomarker results: plasma-/PET-, plasma+/PET-, plasma-/PET+, and plasma+/PET+. MAIN OUTCOMES AND MEASURES: Clinical characteristics were compared between the 4 groups, focusing on the discordant groups. RESULTS: A total of 2611 participants (mean [SD] age was 71.2 [8.7] years; 1656 female [63.4%]), of whom 124 additionally underwent tau PET, were included. Among the plasma biomarkers, phosphorylated tau (p-tau) 217 exhibited the highest concordance rate with Aβ (2326 of 2571 [90.5%]) and tau (100 of 120 [83.3%]) PET. The p-tau217+/Aβ PET- group was older (mean [SD] age, 75.8 [7.2] years vs 70.0 [8.8] years; P < .001) with a higher prevalence of hypertension (56 of 152 [36.8%] vs 266 of 1073 [25.0%]), diabetes (40 of 152 [26.3%] vs 156 of 1059 [14.7%]), and chronic kidney disease (17 of 152 [11.2%] vs 21 of 1073 [2.0%]) compared with the p-tau217-/Aβ PET- group (P < .001 for all). Body mass index was higher in p-tau217-/Aβ PET+ than in p-tau217+/Aβ PET+ (mean [SD], 24.1 [2.8] vs 23.1 [3.1], respectively; P = .001; calculated as weight in kilograms divided by height in meters squared). The p-tau217+/Aβ PET- group had lower hippocampal volume (mean [SD], 2555.4 [576.9] vs 2979.1 [545.8]; P < .001) and worse clinical trajectory compared with p-tau217-/Aβ PET- (β = -0.53; P < .001). In contrast, tau PET discordant cases did not show significant differences in medical comorbidities or clinical outcomes compared with the p-tau217-/tau PET- group. Only the p-tau 217+/tau PET+ group demonstrated faster cognitive deterioration compared with the p-tau 217-/tau PET- group (β = -1.66; P < .001). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that the mechanisms underlying the discordance between plasma biomarkers and PET findings may be multifaceted, underscoring the need to consider the temporal dynamics and biological variability of plasma biomarkers.
引用
- Yun J, Shin D, Lee EH, et al. Temporal Dynamics and Biological Variability of Alzheimer Biomarkers. JAMA Neurol. 2025. PMID: 39960728. doi:10.1001/jamaneurol.2024.5263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。